Cambridge Investment Research Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$160M Sell
173,486
-488
-0.3% -$495K 0.41% 35
2025
Q4
$187M Sell
173,974
-2,867
-2% -$2.74M 0.49% 27
2025
Q3
$135M Buy
176,841
+7,198
+4% +$5.36M 0.37% 36
2025
Q2
$132M Buy
169,643
+6,406
+4% +$4.98M 0.4% 34
2025
Q1
$135M Buy
163,237
+4,034
+3% +$3.36M 0.45% 29
2024
Q4
$123M Sell
159,203
-5,631
-3% -$4.66M 0.41% 33
2024
Q3
$146M Sell
164,834
-3,045
-2% -$2.74M 0.5% 21
2024
Q2
$152M Buy
167,879
+2,446
+1% +$1.96M 0.56% 18
2024
Q1
$129M Buy
165,433
+3,559
+2% +$2.53M 0.5% 22
2023
Q4
$94.4M Sell
161,874
-3,784
-2% -$2.21M 0.4% 38
2023
Q3
$89M Sell
165,658
-7,717
-4% -$3.98M 0.42% 38
2023
Q2
$81.3M Buy
173,375
+20,551
+13% +$8.62M 0.37% 44
2023
Q1
$52.5M Buy
152,824
+8,149
+6% +$2.75M 0.26% 67
2022
Q4
$52.9M Buy
144,675
+6,975
+5% +$2.47M 0.27% 69
2022
Q3
$44.5M Buy
137,700
+11,846
+9% +$3.75M 0.25% 69
2022
Q2
$40.8M Sell
125,854
-1,165
-0.9% -$350K 0.22% 87
2022
Q1
$36.4M Buy
127,019
+20,089
+19% +$5.17M 0.17% 112
2021
Q4
$29.5M Buy
106,930
+5,164
+5% +$1.31M 0.13% 162
2021
Q3
$23.5M Sell
101,766
-1,782
-2% -$440K 0.12% 184
2021
Q2
$23.8M Sell
103,548
-3,798
-4% -$763K 0.11% 181
2021
Q1
$20.1M Buy
107,346
+4,046
+4% +$791K 0.11% 194
2020
Q4
$17.4M Sell
103,300
-2,456
-2% -$367K 0.1% 199
2020
Q3
$15.7M Buy
105,756
+5,314
+5% +$822K 0.11% 200
2020
Q2
$16.5M Buy
100,442
+3,153
+3% +$484K 0.12% 179
2020
Q1
$13.5M Sell
97,289
-5,648
-5% -$776K 0.13% 166
2019
Q4
$13.5M Buy
102,937
+2,737
+3% +$317K 0.1% 200
2019
Q3
$11.2M Sell
100,200
-2,082
-2% -$232K 0.1% 214
2019
Q2
$11.3M Sell
102,282
-911
-0.9% -$107K 0.1% 198
2019
Q1
$13.4M Sell
103,193
-49,451
-32% -$6.01M 0.13% 162
2018
Q4
$17.7M Sell
152,644
-2,549
-2% -$285K 0.2% 112
2018
Q3
$16.7M Buy
155,193
+5,889
+4% +$589K 0.16% 141
2018
Q2
$12.7M Sell
149,304
-4,648
-3% -$382K 0.13% 153
2018
Q1
$11.9M Buy
153,952
+47,938
+45% +$3.86M 0.13% 152
2017
Q4
$8.95M Buy
106,014
+6,830
+7% +$581K 0.11% 187
2017
Q3
$8.48M Buy
99,184
+13,542
+16% +$1.11M 0.11% 167
2017
Q2
$7.05M Buy
85,642
+8,157
+11% +$665K 0.1% 180
2017
Q1
$6.52M Buy
77,485
+1,076
+1% +$86.2K 0.11% 171
2016
Q4
$5.62M Buy
76,409
+3,242
+4% +$241K 0.11% 178
2016
Q3
$5.87M Buy
73,167
+1,460
+2% +$117K 0.11% 166
2016
Q2
$5.65M Buy
71,707
+2,569
+4% +$193K 0.12% 158
2016
Q1
$4.98M Sell
69,138
-1,861
-3% -$141K 0.11% 165
2015
Q4
$5.98M Buy
70,999
+8,297
+13% +$689K 0.14% 137
2015
Q3
$5.25M Buy
62,702
+790
+1% +$66.7K 0.15% 137
2015
Q2
$5.17M Sell
61,912
-472
-0.8% -$36K 0.14% 146
2015
Q1
$4.53M Sell
62,384
-11,575
-16% -$824K 0.13% 162
2014
Q4
$5.1M Buy
73,959
+2,225
+3% +$150K 0.16% 127
2014
Q3
$4.65M Buy
71,734
+3,425
+5% +$217K 0.14% 151
2014
Q2
$4.25M Buy
68,309
+237
+0.3% +$14.1K 0.15% 136
2014
Q1
$4.01M Buy
68,072
+1,198
+2% +$66.9K 0.15% 133
2013
Q4
$3.41M Sell
66,874
-4,744
-7% -$238K 0.14% 145
2013
Q3
$3.6M Sell
71,618
-8,308
-10% -$435K 0.16% 133
2013
Q2
$3.93M Buy
+79,926
New +$4.35M 0.2% 108

Other funds holding LLY

Cambridge Investment Research Advisors's LLY Position: Q1 2026 in Review

Cambridge Investment Research Advisors reduced its Eli Lilly (LLY) stake by 0.28% in Q1 2026, selling an estimated $495K and leaving 173,486 shares worth $160M. The position accounts for 0.41% of the portfolio, ranked #35.

Cambridge Investment Research Advisors first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $187M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Cambridge Investment Research Advisors held 173,486 shares of Eli Lilly worth $160M as of Q1 2026.
  • Cambridge Investment Research Advisors sold 488 Eli Lilly shares in Q1 2026, an estimated $495K.
  • Eli Lilly made up 0.41% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #35 holding.
  • Cambridge Investment Research Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Cambridge Investment Research Advisors's Eli Lilly position peaked at $187M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.